1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Reardon, P.N. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 111 1391 1396 10.1073/pnas.1309842111 24474763 Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer. 2014 10.2210/pdb2lp7/pdb pdb_00002lp7 7010.809 Envelope glycoprotein 3 man polymer no no GYIPEAPRDGQAYVRKDGEWVLLSTFLGSSGNEQELLELDKWASLWNWFNITNWLWYIK GYIPEAPRDGQAYVRKDGEWVLLSTFLGSSGNEQELLELDKWASLWNWFNITNWLWYIK A,B,C polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n sample 11676 Human immunodeficiency virus 1 562 Escherichia coli pTCLE database_2 pdbx_database_status pdbx_nmr_software pdbx_nmr_spectrometer repository Initial release Database references Database references Data collection Database references Other 1 0 2013-02-06 1 1 2014-01-15 1 2 2014-03-05 1 3 2023-06-14 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model BMRB Y RCSB 2012-02-03 REL REL REL REL structures with the least restraint violations 400 11 2D 1H-15N HSQC 3D HNCA 3D HNCACB 3D HN(CO)CA 3D 1H-15N NOESY 50 mM 100 mM [U-99% 2H] 6.0 ambient 30 K simulated annealing 1 lowest energy 50 mM sodium phosphate, 100 mM [U-99% 2H] DPC, 90% H2O/10% D2O 90% H2O/10% D2O Schwieters, Kuszewski, Tjandra and Clore structure solution X-PLOR NIH Schwieters, Kuszewski, Tjandra and Clore refinement X-PLOR NIH 800 Varian INOVA Varian INOVA 600 Varian INOVA Varian INOVA 950 Bruker AVANCE Bruker Avance GLY 1 n 1 GLY 1 A TYR 2 n 2 TYR 2 A ILE 3 n 3 ILE 3 A PRO 4 n 4 PRO 4 A GLU 5 n 5 GLU 5 A ALA 6 n 6 ALA 6 A PRO 7 n 7 PRO 7 A ARG 8 n 8 ARG 8 A ASP 9 n 9 ASP 9 A GLY 10 n 10 GLY 10 A GLN 11 n 11 GLN 11 A ALA 12 n 12 ALA 12 A TYR 13 n 13 TYR 13 A VAL 14 n 14 VAL 14 A ARG 15 n 15 ARG 15 A LYS 16 n 16 LYS 16 A ASP 17 n 17 ASP 17 A GLY 18 n 18 GLY 18 A GLU 19 n 19 GLU 19 A TRP 20 n 20 TRP 20 A VAL 21 n 21 VAL 21 A LEU 22 n 22 LEU 22 A LEU 23 n 23 LEU 23 A SER 24 n 24 SER 24 A THR 25 n 25 THR 25 A PHE 26 n 26 PHE 26 A LEU 27 n 27 LEU 27 A GLY 28 n 28 GLY 28 A SER 29 n 29 SER 29 A SER 30 n 30 SER 30 A GLY 31 n 31 GLY 31 A ASN 32 n 32 ASN 32 A GLU 33 n 33 GLU 33 A GLN 34 n 34 GLN 34 A GLU 35 n 35 GLU 35 A LEU 36 n 36 LEU 36 A LEU 37 n 37 LEU 37 A GLU 38 n 38 GLU 38 A LEU 39 n 39 LEU 39 A ASP 40 n 40 ASP 40 A LYS 41 n 41 LYS 41 A TRP 42 n 42 TRP 42 A ALA 43 n 43 ALA 43 A SER 44 n 44 SER 44 A LEU 45 n 45 LEU 45 A TRP 46 n 46 TRP 46 A ASN 47 n 47 ASN 47 A TRP 48 n 48 TRP 48 A PHE 49 n 49 PHE 49 A ASN 50 n 50 ASN 50 A ILE 51 n 51 ILE 51 A THR 52 n 52 THR 52 A ASN 53 n 53 ASN 53 A TRP 54 n 54 TRP 54 A LEU 55 n 55 LEU 55 A TRP 56 n 56 TRP 56 A TYR 57 n 57 TYR 57 A ILE 58 n 58 ILE 58 A LYS 59 n 59 LYS 59 A GLY 1 n 1 GLY 1 B TYR 2 n 2 TYR 2 B ILE 3 n 3 ILE 3 B PRO 4 n 4 PRO 4 B GLU 5 n 5 GLU 5 B ALA 6 n 6 ALA 6 B PRO 7 n 7 PRO 7 B ARG 8 n 8 ARG 8 B ASP 9 n 9 ASP 9 B GLY 10 n 10 GLY 10 B GLN 11 n 11 GLN 11 B ALA 12 n 12 ALA 12 B TYR 13 n 13 TYR 13 B VAL 14 n 14 VAL 14 B ARG 15 n 15 ARG 15 B LYS 16 n 16 LYS 16 B ASP 17 n 17 ASP 17 B GLY 18 n 18 GLY 18 B GLU 19 n 19 GLU 19 B TRP 20 n 20 TRP 20 B VAL 21 n 21 VAL 21 B LEU 22 n 22 LEU 22 B LEU 23 n 23 LEU 23 B SER 24 n 24 SER 24 B THR 25 n 25 THR 25 B PHE 26 n 26 PHE 26 B LEU 27 n 27 LEU 27 B GLY 28 n 28 GLY 28 B SER 29 n 29 SER 29 B SER 30 n 30 SER 30 B GLY 31 n 31 GLY 31 B ASN 32 n 32 ASN 32 B GLU 33 n 33 GLU 33 B GLN 34 n 34 GLN 34 B GLU 35 n 35 GLU 35 B LEU 36 n 36 LEU 36 B LEU 37 n 37 LEU 37 B GLU 38 n 38 GLU 38 B LEU 39 n 39 LEU 39 B ASP 40 n 40 ASP 40 B LYS 41 n 41 LYS 41 B TRP 42 n 42 TRP 42 B ALA 43 n 43 ALA 43 B SER 44 n 44 SER 44 B LEU 45 n 45 LEU 45 B TRP 46 n 46 TRP 46 B ASN 47 n 47 ASN 47 B TRP 48 n 48 TRP 48 B PHE 49 n 49 PHE 49 B ASN 50 n 50 ASN 50 B ILE 51 n 51 ILE 51 B THR 52 n 52 THR 52 B ASN 53 n 53 ASN 53 B TRP 54 n 54 TRP 54 B LEU 55 n 55 LEU 55 B TRP 56 n 56 TRP 56 B TYR 57 n 57 TYR 57 B ILE 58 n 58 ILE 58 B LYS 59 n 59 LYS 59 B GLY 1 n 1 GLY 1 C TYR 2 n 2 TYR 2 C ILE 3 n 3 ILE 3 C PRO 4 n 4 PRO 4 C GLU 5 n 5 GLU 5 C ALA 6 n 6 ALA 6 C PRO 7 n 7 PRO 7 C ARG 8 n 8 ARG 8 C ASP 9 n 9 ASP 9 C GLY 10 n 10 GLY 10 C GLN 11 n 11 GLN 11 C ALA 12 n 12 ALA 12 C TYR 13 n 13 TYR 13 C VAL 14 n 14 VAL 14 C ARG 15 n 15 ARG 15 C LYS 16 n 16 LYS 16 C ASP 17 n 17 ASP 17 C GLY 18 n 18 GLY 18 C GLU 19 n 19 GLU 19 C TRP 20 n 20 TRP 20 C VAL 21 n 21 VAL 21 C LEU 22 n 22 LEU 22 C LEU 23 n 23 LEU 23 C SER 24 n 24 SER 24 C THR 25 n 25 THR 25 C PHE 26 n 26 PHE 26 C LEU 27 n 27 LEU 27 C GLY 28 n 28 GLY 28 C SER 29 n 29 SER 29 C SER 30 n 30 SER 30 C GLY 31 n 31 GLY 31 C ASN 32 n 32 ASN 32 C GLU 33 n 33 GLU 33 C GLN 34 n 34 GLN 34 C GLU 35 n 35 GLU 35 C LEU 36 n 36 LEU 36 C LEU 37 n 37 LEU 37 C GLU 38 n 38 GLU 38 C LEU 39 n 39 LEU 39 C ASP 40 n 40 ASP 40 C LYS 41 n 41 LYS 41 C TRP 42 n 42 TRP 42 C ALA 43 n 43 ALA 43 C SER 44 n 44 SER 44 C LEU 45 n 45 LEU 45 C TRP 46 n 46 TRP 46 C ASN 47 n 47 ASN 47 C TRP 48 n 48 TRP 48 C PHE 49 n 49 PHE 49 C ASN 50 n 50 ASN 50 C ILE 51 n 51 ILE 51 C THR 52 n 52 THR 52 C ASN 53 n 53 ASN 53 C TRP 54 n 54 TRP 54 C LEU 55 n 55 LEU 55 C TRP 56 n 56 TRP 56 C TYR 57 n 57 TYR 57 C ILE 58 n 58 ILE 58 C LYS 59 n 59 LYS 59 C author_defined_assembly 3 trimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 B O GLU 19 B O GLU 19 B N LYS 16 B N LYS 16 B O ARG 15 B O ARG 15 A N TYR 13 A N TYR 13 A N VAL 14 A N VAL 14 A O VAL 21 A O VAL 21 A O VAL 21 A O VAL 21 A N VAL 14 A N VAL 14 A N ARG 15 A N ARG 15 C O TYR 13 C O TYR 13 C N LYS 16 C N LYS 16 C O GLU 19 C O GLU 19 C O ARG 15 C O ARG 15 B N TYR 13 B N TYR 13 4 B B O H LEU TRP 45 48 1.58 8 B B H1 H GLY TYR 1 2 1.31 9 C C H3 H GLY TYR 1 2 1.33 9 C C O H LEU PHE 23 26 1.59 11 B B O H LEU TRP 45 48 1.59 1 A ILE 3 -157.81 51.93 1 A GLU 5 172.37 107.87 1 A ASN 32 -162.61 -5.94 1 B PRO 4 -44.82 -75.48 1 B GLU 5 162.45 -29.64 1 B ALA 6 74.48 144.62 1 B ASP 9 -140.48 10.64 1 B ASP 17 38.33 41.60 1 B SER 29 -160.06 56.37 1 B SER 30 -162.91 86.48 1 B ASN 32 -161.26 -14.54 1 B PHE 49 -60.65 7.01 1 C ASP 17 38.55 38.81 1 C SER 29 45.54 102.25 1 C SER 30 79.22 -24.78 1 C ASN 32 -162.13 -8.13 2 A ILE 3 51.92 95.36 2 A GLU 5 164.46 131.13 2 A SER 29 -79.44 -169.80 2 A SER 30 78.28 -48.90 2 A ASN 32 -74.90 27.40 2 B ILE 3 60.57 88.42 2 B PRO 4 -49.40 -178.37 2 B GLU 5 -61.75 -145.23 2 B ASP 17 37.89 44.11 2 B SER 30 42.92 22.22 2 B ASN 32 -164.31 -8.29 2 B PHE 49 -64.38 6.58 2 C ILE 3 47.72 74.03 2 C PRO 7 -54.06 99.91 2 C ASP 17 37.60 37.02 2 C SER 29 54.61 154.17 2 C SER 30 42.90 22.15 2 C ASN 32 81.07 -6.16 2 C LEU 36 -67.35 0.87 2 C PHE 49 -46.37 -18.26 3 A ILE 3 56.04 71.72 3 A GLU 5 -62.39 -147.88 3 A SER 30 78.55 -35.66 3 A ASN 32 -75.14 26.88 3 B TYR 2 -147.19 -132.77 3 B PRO 4 -67.14 -85.46 3 B GLU 5 169.83 115.01 3 B ASP 17 38.31 42.30 3 B ASN 32 -163.91 -6.22 3 C ILE 3 43.95 72.62 3 C PRO 4 -54.47 172.81 3 C GLU 5 -55.95 170.02 3 C ASN 32 -163.84 -7.45 4 A ALA 6 155.26 -38.89 4 A PRO 7 -66.73 59.12 4 A ARG 8 -103.53 75.07 4 A SER 29 42.10 94.21 4 A SER 30 77.14 -30.78 4 A ASN 32 -161.60 -12.82 4 B GLU 5 178.06 -43.34 4 B ALA 6 74.79 94.92 4 B PRO 7 -47.60 176.75 4 B ASP 17 39.31 43.45 4 B SER 30 78.31 -26.74 4 B ASN 32 -163.00 -13.51 4 B PHE 49 -45.16 -18.17 4 C TYR 2 47.42 72.38 4 C GLU 5 -179.13 -107.63 4 C ALA 6 67.71 70.02 4 C ASP 9 -152.29 3.05 4 C ASP 17 38.35 40.16 4 C SER 29 53.09 112.17 4 C SER 30 78.89 -27.69 4 C ASN 32 -162.93 -13.37 4 C PHE 49 -67.26 7.79 5 A ILE 3 52.55 70.96 5 A GLU 5 -59.97 -179.80 5 A ASP 17 39.17 47.06 5 A SER 29 -79.63 -163.90 5 A SER 30 77.90 -36.40 5 A ASN 32 -74.82 25.27 5 A PHE 49 -65.47 7.58 5 B TYR 2 -45.49 165.53 5 B PRO 4 -46.98 164.83 5 B GLU 5 -51.25 -179.51 5 B SER 29 -159.83 -127.83 5 B SER 30 77.71 -35.38 5 B PHE 49 -45.43 -18.12 5 C TYR 2 -153.67 1.37 5 C PRO 4 -51.90 173.73 5 C GLU 5 -52.51 179.34 5 C ASP 17 39.31 45.22 5 C SER 29 -79.92 -141.03 6 A ILE 3 -36.76 130.98 6 A GLU 5 -165.39 -130.85 6 A ALA 6 171.92 76.53 6 A PRO 7 -49.38 155.13 6 A ASP 17 39.44 44.11 6 A SER 30 80.30 -68.60 6 A ASN 32 -163.81 -7.00 6 B ILE 3 17.37 70.08 6 B GLU 5 -169.39 -132.98 6 B ALA 6 171.49 78.72 6 B ASP 17 37.84 41.68 6 B SER 29 -79.33 -169.06 6 B SER 30 77.59 -36.40 6 B ASN 32 -75.40 27.31 6 B PHE 49 -67.57 7.59 6 C PRO 4 -43.60 -76.02 6 C GLU 5 173.22 -27.19 6 C ALA 6 74.76 144.84 6 C ASP 17 38.10 41.97 6 C SER 29 -79.18 -168.70 6 C SER 30 78.12 -37.12 6 C ASN 32 -75.39 28.66 7 A TYR 2 47.40 91.51 7 A GLU 5 -163.19 101.92 7 A ASP 17 38.46 43.67 7 A SER 30 -162.25 -23.56 7 B TYR 2 -150.90 -158.45 7 B PRO 4 -77.69 -162.45 7 B GLU 5 61.93 150.17 7 B ALA 6 179.50 74.18 7 B PRO 7 -47.16 151.92 7 B ASP 17 37.35 40.84 7 B LEU 27 -73.95 -75.62 7 B SER 29 41.19 89.51 7 B SER 30 76.13 -27.37 7 B ASN 32 -160.90 -12.08 7 B PHE 49 -45.07 -19.09 7 C ILE 3 52.12 97.52 7 C PRO 4 -45.23 -71.70 7 C GLU 5 171.94 126.67 7 C ASP 17 39.75 38.60 7 C SER 29 58.03 138.40 7 C ASN 32 -161.93 -20.48 7 C PHE 49 -45.05 -19.47 8 A TYR 2 -146.12 36.92 8 A PRO 4 -55.70 93.68 8 A GLU 5 179.72 96.98 8 A ASN 32 -163.28 -6.63 8 B GLU 5 -179.77 -39.77 8 B ALA 6 73.57 86.54 8 B PRO 7 -50.14 -175.88 8 B ASP 17 38.67 40.13 8 B SER 30 80.34 2.61 8 B ASN 32 -164.62 -5.30 8 C TYR 2 -148.20 -5.24 8 C GLU 5 -174.95 -118.20 8 C ALA 6 166.40 84.96 8 C PRO 7 -48.71 150.03 8 C ASP 17 39.25 36.33 8 C SER 30 78.42 -34.21 8 C ASN 32 -75.46 27.26 9 A TYR 2 -144.86 -127.11 9 A GLU 5 -170.41 119.66 9 A ALA 6 -153.55 -45.04 9 A ASP 9 -150.66 14.18 9 A ASP 17 39.85 46.69 9 A SER 30 79.07 -36.32 9 A ASN 32 -75.59 31.61 9 B TYR 2 53.83 171.84 9 B ILE 3 44.33 74.17 9 B PRO 4 -54.79 -140.16 9 B GLU 5 -107.19 -169.32 9 B ALA 6 -167.93 72.37 9 B ASP 17 39.37 40.57 9 B SER 30 78.59 -37.90 9 B ASN 32 -75.18 28.38 9 B PHE 49 -45.87 -17.52 9 C ILE 3 58.78 95.44 9 C PRO 4 -45.06 -70.40 9 C GLU 5 170.92 128.08 9 C ASP 17 38.84 41.75 9 C SER 30 79.04 -42.54 9 C ASN 32 -74.44 30.65 10 A PRO 4 -66.86 -72.95 10 A GLU 5 176.89 -37.08 10 A ALA 6 62.55 149.86 10 A ASP 17 39.78 42.15 10 A SER 29 54.37 129.91 10 A ASN 32 -161.21 -14.71 10 B TYR 13 -140.62 -151.11 10 B ASP 17 39.60 43.25 10 B SER 30 -163.82 -42.93 10 B ASN 32 -76.41 22.71 10 C PRO 4 -43.41 -72.84 10 C GLU 5 165.46 121.50 10 C ASP 17 38.68 43.30 10 C SER 30 77.24 -0.36 10 C ASN 32 -163.68 -4.42 11 A TYR 2 -153.16 12.88 11 A PRO 4 -61.22 -173.38 11 A GLU 5 67.24 140.64 11 A ALA 6 179.03 74.72 11 A ASN 32 -162.98 -13.04 11 B GLU 5 -170.77 -106.57 11 B ALA 6 73.46 144.32 11 B ASP 17 39.59 45.75 11 B ASN 32 -162.20 -9.28 11 B PHE 49 -45.31 -17.92 11 C TYR 2 -150.11 -28.81 11 C GLU 5 -52.47 178.48 11 C ASP 17 38.49 45.62 11 C SER 29 48.59 -111.03 11 C ASN 32 -163.29 -16.86 lowest energy, model 8 Structure of gp41-M-MAT, a membrane associated MPER trimer from HIV-1 gp41. 1 N N 1 N N 1 N N A LEU 23 A LEU 23 HELX_P A GLY 28 A GLY 28 1 1 6 A ASN 32 A ASN 32 HELX_P A PHE 49 A PHE 49 1 2 18 A PHE 49 A PHE 49 HELX_P A LYS 59 A LYS 59 1 3 11 B LEU 23 B LEU 23 HELX_P B GLY 28 B GLY 28 1 4 6 B ASN 32 B ASN 32 HELX_P B PHE 49 B PHE 49 1 5 18 B PHE 49 B PHE 49 HELX_P B LYS 59 B LYS 59 1 6 11 C LEU 22 C LEU 22 HELX_P C GLY 28 C GLY 28 1 7 7 C ASN 32 C ASN 32 HELX_P C PHE 49 C PHE 49 1 8 18 C ASN 50 C ASN 50 HELX_P C LYS 59 C LYS 59 1 9 10 VIRAL PROTEIN gp41, VIRAL PROTEIN 2LP7 PDB 1 2LP7 1 59 2LP7 1 59 2LP7 A 1 1 59 1 59 2LP7 1 59 2LP7 B 1 1 59 1 59 2LP7 1 59 2LP7 C 1 1 59 7 2 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel B GLU 19 B GLU 19 B VAL 21 B VAL 21 B ALA 12 B ALA 12 B LYS 16 B LYS 16 A ALA 12 A ALA 12 A LYS 16 A LYS 16 A GLU 19 A GLU 19 A LEU 22 A LEU 22 A ALA 12 A ALA 12 A LYS 16 A LYS 16 C ALA 12 C ALA 12 C LYS 16 C LYS 16 C GLU 19 C GLU 19 C VAL 21 C VAL 21 C ALA 12 C ALA 12 C LYS 16 C LYS 16 B ALA 12 B ALA 12 B LYS 16 B LYS 16